CARD9 Forms an Alternative CBM Complex in Richter Syndrome

Simple Summary: The transformation process of chronic lymphocytic leukemia into an aggressive lymphoma, called Richter syndrome (RS), is incompletely understood, and therapeutic options are limited. Here, we report CARD9 to be expressed in a subset of RS tissue specimen and in the first and only available RS cell line, U-RT1. In U-RT1, CARD9 attaches to BCL10 and MALT1, and knockdown of CARD9 leads to a significant reduction in cell viability. We hypothesized that CARD9 plays an oncogenic role in RS through the activation of NF-kappa B signaling. Our findings may help to extend the current knowledge about the pathogenesis of RS and promote the development of targeted therapies for this aggressive disease.Richter syndrome (RS) is defined as the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, mostly diffuse large B-cell lymphoma (DLBCL). Despite intensive therapy, patients with RS have an unfavorable clinical outcome. The detailed pathobiology of Richter transformation still needs to be elucidated. Here, we report high mRNA and protein levels of CARD9 in the RS cell line U-RT1. Co-immunoprecipitation revealed the assembly of a CBM complex using CARD9 instead of CARD11. CARD9 is known to be an activator of NF-kB signaling in myeloid cells. U-RT1 Western blot analyses showed phosphorylation of I kappa B as well as IKK, indicating a constitutively active canonical NF-kB pathway. This was further supported by the significant reduction in cell viability and CYLD cleavage products after CARD9 siRNA knockdown. We also showed immunostaining for CARD9 in 53% of cases analyzed in a series of RS tissue specimens, whereas other lymphomas rarely show CARD9 expression. This is the first report on ectopic expression and function of CARD9 in an aggressive B-cell lymphoma. Our findings suggest that CARD9 may contribute to the pathogenesis of RS.

Automated summary

This study reports high levels of mRNA and protein expression of CARD9 in the RS cell line U-RT1. Co-immunoprecipitation revealed the assembly of a CBM complex using CARD9 instead of CARD11. Western blot analyses showed phosphorylation of IκB and IKK in U-RT1, indicating a constitutively active canonical NF-kB pathway. Knockdown of CARD9 resulted in a significant reduction in cell viability and CYLD cleavage products. Immunostaining for CARD9 was also observed in 53% of RS tissue specimen cases analyzed. This is the first report on the ectopic expression and function of CARD9 in an aggressive B-cell lymphoma, suggesting that CARD9 may contribute to the pathogenesis of RS.